HIV-infected macrophages are infected and killed by the interferon-sensitive Rhabdovirus, MG1.

The use of unique, cell surface markers to target and eradicate HIV-infected cells has been a longstanding objective of HIV-1 cure research. This approach, however, overlooks the possibility that intracellular changes present within HIV-infected cells may serve as valuable therapeutic targets. For example, the identification of dysregulated antiviral signalling in cancer has led to the characterization of oncolytic viruses capable of preferentially killing cancer cells. Since impairment of cellular antiviral machinery has been proposed as a mechanism by which HIV-1 evades immune clearance, we hypothesized that HIV-infected macrophages (an important viral reservoir in vivo) would be preferentially killed by the interferon-sensitive oncolytic Maraba virus, MG1. We first showed that HIV-infected monocyte-derived macrophages (MDM) were more susceptible to MG1 infection and killing than HIV-uninfected cells. As MG1 is highly sensitive to type I interferons (IFN1), we then investigated whether we could identify IFN1 signalling differences between HIV-infected and uninfected MDM and found evidence of impaired IFNα responsiveness within HIV-infected cells. Finally, to assess whether MG1 could target a relevant, primary cell reservoir of HIV-1, we investigated its effects in alveolar macrophages (AM) obtained from effectively-treated individuals living with HIV-1. As observed with in vitro infected MDM, we found that HIV-infected AM were preferentially eliminated by MG1. In summary, the oncolytic Rhabdovirus, MG1, appears to preferentially target and kill HIV-infected cells via impairment of antiviral signalling pathways and may therefore provide a novel approach to an HIV-1 cure.IMPORTANCE: Human Immunodeficiency Virus 1 (HIV-1) remains a treatable, but incurable, viral infection. The establishment of viral reservoirs containing latently infected cells remains the main obstacle in the search for a cure. Cure research has also focused on only one cellular target of HIV-1 (the CD4 + T cell), while largely overlooking others (such as macrophages) that contribute to HIV-1 persistence. In this study, we address these challenges by describing a potential strategy for the eradication of HIV-infected macrophages. Specifically, we show that an engineered Rhabdovirus-initially developed as a cancer therapy-is capable of preferential infection and killing of HIV-infected macrophages, possibly via the same altered antiviral signalling seen in cancer cells. As this Rhabdovirus is currently being explored in Phase I/II clinical trials, there is potential for this approach to be readily adapted for use within the HIV-1 cure field.